Live Biotherapeutic Products and Microbiome CDMO

Global Live Biotherapeutic Products and Microbiome CDMO Market to Reach US$627.7 Million by 2030

The global market for Live Biotherapeutic Products and Microbiome CDMO estimated at US$94.6 Million in the year 2024, is expected to reach US$627.7 Million by 2030, growing at a CAGR of 37.1% over the analysis period 2024-2030. C.difficle, one of the segments analyzed in the report, is expected to record a 37.7% CAGR and reach US$276.8 Million by the end of the analysis period. Growth in the Crohn`s Disease segment is estimated at 37.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.9 Million While China is Forecast to Grow at 35.1% CAGR

The Live Biotherapeutic Products and Microbiome CDMO market in the U.S. is estimated at US$24.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.4 Million by the year 2030 trailing a CAGR of 35.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 33.9% and 32.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 25.8% CAGR.

Global Live Biotherapeutic Products and Microbiome CDMO Market – Key Trends & Drivers Summarized

Why Is the Market for Live Biotherapeutic Products and Microbiome CDMO Expanding Rapidly?

The increasing understanding of the human microbiome’s role in health and disease has fueled significant growth in live biotherapeutic products (LBPs) and microbiome contract development and manufacturing organizations (CDMOs). LBPs, which consist of living microorganisms offering therapeutic benefits, are gaining traction in treating gastrointestinal, metabolic, immunological, and neurological disorders. As microbiome research advances, pharmaceutical companies are heavily investing in LBP development, necessitating the support of specialized CDMOs to ensure regulatory compliance and scalable manufacturing. The shift toward precision medicine and the demand for personalized microbiome-based therapies are also driving the expansion of the sector. Additionally, regulatory agencies such as the FDA and EMA are providing clearer guidelines for LBPs, accelerating their commercialization. The growing prevalence of chronic diseases and the rise in antibiotic-resistant infections have further solidified the need for microbiome-based interventions. As awareness of microbiome-targeted treatments rises among consumers and healthcare providers, the LBP market is expected to witness exponential growth.

What Innovations Are Driving Growth in Live Biotherapeutics and Microbiome CDMO Services?

Technological advancements are significantly enhancing the development and scalability of live biotherapeutic products. One of the key breakthroughs is the application of artificial intelligence (AI) and machine learning in microbiome analysis, enabling researchers to identify beneficial bacterial strains more efficiently. Next-generation sequencing (NGS) and metagenomics are providing deeper insights into microbial diversity, allowing for the design of targeted LBP formulations. Innovations in fermentation technology and bioprocessing are improving large-scale production, ensuring consistent quality and viability of live microbial therapeutics. Freeze-drying and encapsulation techniques are also improving stability and shelf-life, addressing challenges associated with microbial viability. Additionally, microbiome CDMOs are integrating automated manufacturing systems and real-time quality control analytics to optimize production processes. The use of synthetic biology to engineer probiotics with enhanced functionalities is further expanding the potential applications of LBPs. With continued research and innovation, live biotherapeutic products are becoming safer, more effective, and commercially viable at scale.

How Are Consumer Trends and Industry Collaborations Shaping the Market?

The rising consumer demand for microbiome-based therapies and probiotic-driven health solutions is reshaping the live biotherapeutic products market. Consumers are increasingly prioritizing gut health and its connection to immunity, mental health, and metabolic balance, leading to heightened interest in microbiome-based interventions. Direct-to-consumer (DTC) microbiome solutions, such as personalized probiotic regimens and microbiome testing kits, are also gaining popularity, fueling market expansion. Industry collaborations between pharmaceutical companies, biotech firms, and CDMOs are accelerating research and development efforts, leading to faster commercialization of microbiome-based therapies. Regulatory agencies are streamlining approval processes for LBPs, facilitating quicker market entry and greater consumer access. Additionally, increased venture capital and private equity investments in microbiome research startups are providing funding for further innovations. As consumers continue to seek science-backed microbiome solutions, and industry stakeholders forge strategic partnerships, the live biotherapeutic products market is expected to experience sustained growth.

What Are the Key Growth Drivers Fueling the Live Biotherapeutic Products and Microbiome CDMO Market?

The growth in the live biotherapeutic products and microbiome CDMO market is driven by multiple factors, including the rising prevalence of chronic diseases, increasing investments in microbiome research, and evolving regulatory frameworks. One of the primary drivers is the expanding role of LBPs in addressing conditions such as inflammatory bowel disease (IBD), obesity, and metabolic disorders. The growing body of clinical evidence supporting the efficacy of microbiome-based interventions is prompting pharmaceutical companies to accelerate product development. The involvement of microbiome CDMOs is crucial in ensuring scalable, high-quality production of LBPs, enabling their broader adoption. Additionally, advancements in synthetic biology and bioengineering are optimizing microbial strain selection, enhancing therapeutic efficacy. The emergence of microbiome-based precision medicine is also contributing to market growth, as researchers develop targeted therapies based on individual microbiota compositions. Increasing consumer awareness of gut health, coupled with government initiatives to promote probiotic-based treatments, is further supporting the expansion of the market. With ongoing innovation and investment, the live biotherapeutic products and microbiome CDMO industry is poised for significant growth, transforming modern healthcare and therapeutic approaches.

SCOPE OF STUDY:

The report analyzes the Live Biotherapeutic Products and Microbiome CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (C.difficle, Crohn`s Disease, IBS, Diabetes, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• 4D Pharma plc
• Arrant Bio
• Assembly Biosciences, Inc.
• Bacthera
• Biose Industrie
• Cerbios-Pharma SA
• Freya Biosciences
• Genetic Analysis
• Genome & Company
• Inpac Probiotics
• Lallemand Health Solutions
• List Biological Laboratories, Inc.
• Lonza Group
• Microbiotica
• NIZO Food Research
• Quay Pharmaceuticals
• Rebiotix Inc. (A Ferring Company)
• Seres Therapeutics
• Siolta Therapeutics
• Wacker Biotech

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.